RHINOCORT ALLERGY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RHINOCORT ALLERGY (RHINOCORT ALLERGY).
Budesonide is a corticosteroid with potent anti-inflammatory activity. It inhibits multiple inflammatory cell types and mediators, reducing nasal congestion, sneezing, and rhinorrhea.
| Metabolism | Budesonide undergoes extensive first-pass metabolism in the liver via CYP3A4 to form two major metabolites (16α-hydroxyprednisolone and 6β-hydroxybudesonide) which have minimal glucocorticoid activity. |
| Excretion | Primarily hepatic metabolism via CYP3A4, followed by renal excretion of inactive metabolites (approximately 80% in urine) and biliary/fecal elimination (20%). Less than 2% unchanged drug in urine. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours. Intranasal administration results in minimal systemic absorption, so clinical effect duration is determined by local tissue retention rather than plasma half-life. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.0 L/kg. This indicates extensive tissue distribution, but clinical relevance is limited due to primarily local action. |
| Bioavailability | Intranasal administration results in low systemic bioavailability due to limited absorption and first-pass metabolism. Systemic bioavailability is less than 1% (approximately 0.1-0.5% of the administered dose). |
| Onset of Action | Intranasal: Onset of symptomatic relief begins within 10-12 hours after first dose, with maximum effect achieved after 1-2 weeks of regular use. |
| Duration of Action | Intranasal: Duration of clinical effect is dose-dependent, typically 24 hours after a single dose. Regular once-daily dosing provides sustained symptom control due to local anti-inflammatory effects. |
| Molecular Weight | 430.53 |
1-2 sprays per nostril once daily; intranasal route.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 6-12 years: 1 spray per nostril once daily; maximum 1 spray/nostril/day. Not recommended for children under 6 years. |
| Geriatric use | Same as adult dosing; no specific dose adjustment necessary. |
| 1st trimester | Limited data; intranasal corticosteroids are generally avoided unless benefit clearly outweighs risk. Animal studies show no teratogenicity at low doses. |
| 2nd trimester | Use only if clearly needed; no known fetal harm reported. Consider lowest effective dose. |
| 3rd trimester | Use with caution near term; potential for fetal adrenal suppression if high doses are used systemically, though intranasal route minimizes systemic exposure. |
Clinical note
Comprehensive clinical and safety monograph for RHINOCORT ALLERGY (RHINOCORT ALLERGY).
| Placental transfer | Crosses placenta minimally after intranasal administration; animal studies indicate low transfer. Systemic bioavailability is <1% after intranasal use. |
| Breastfeeding | Budesonide is excreted into breast milk in low amounts. Intranasal use results in minimal systemic absorption, unlikely to affect the infant. Consider benefits of treatment against potential risks. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to budesonide or any component of the formulationUntreated nasal mucosal infections (e.g., herpes simplex)
| Precautions | Immunosuppression and increased susceptibility to infections, Hypothalamic-pituitary-adrenal axis suppression with long-term use, Local effects including epistaxis, nasal ulceration, and Candida albicans infection, Potential for growth suppression in pediatric patients, Ocular effects such as glaucoma and cataracts |
| Food/Dietary | No known food interactions. Grapefruit juice does not significantly alter intranasal budesonide systemic absorption. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safely Compatible) |
| Teratogenic Risk | Category B. Inhaled budesonide at recommended doses is not associated with increased risk of major malformations. First trimester: no increased risk in human studies. Second and third trimesters: potential for fetal growth restriction with high systemic exposure; minimal risk at intranasal doses. |
| Fetal Monitoring | Monitor maternal adrenal suppression if high doses or prolonged use. Fetal growth assessed by ultrasound if high cumulative exposure. No routine monitoring required for standard intranasal dosing. |
| Fertility Effects | No evidence of impairment of fertility in animal studies or human data. Inhaled corticosteroids at typical doses do not adversely affect fertility. |
| Rhinocort Allergy (budesonide) is an intranasal corticosteroid. Onset of action is typically within 10-12 hours, but maximal benefit may require several days of regular use. For seasonal allergic rhinitis, start treatment 1-2 weeks before expected pollen season. Avoid contact with eyes; if eye exposure occurs, rinse thoroughly with water. Use in patients with active nasal infections (e.g., herpes simplex) should be avoided. Prolonged use may rarely cause nasal septal perforation or elevated intraocular pressure. |
| Patient Advice | Use regularly for best results; it is not for immediate symptom relief. · Shake the bottle gently before each use. · Prime the pump by spraying into the air 10 times if new or not used for 2+ weeks. · Blow your nose gently before administration. · Keep head upright and spray away from the nasal septum to avoid irritation. · Do not exceed recommended dosage (2 sprays per nostril once daily). · Rinse the applicator with warm water after each use and replace cap. · If nasal irritation occurs, reduce frequency or temporarily discontinue. · Do not use with other intranasal corticosteroids unless directed. · Store at room temperature, away from heat and direct light. |